About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 5843 record(s)
Req # A-2022-000257
The number of rapid tests distributed to government employees by department for each month and for each product type since September 2020. The number of rapid tests distributed to the private sector by organization during the same timeframe.Organization: Health Canada
September 2022
Req # A-2022-000371
The Health Canada approval letter for Vertex Pharmaceutical's trial to be carried out in Canada: A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes (ClinicalTrials.gov Identifier: NCT04786262).Organization: Health Canada
September 2022
Req # A-2022-000391
Cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-06-22 for the medicinal ingredient buprenorphine. Screening…Organization: Health Canada
September 2022
Req # A-2022-000392
Cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-06-22 for the medicinal ingredient desmopressin. Screening…Organization: Health Canada
September 2022
Req # A-2022-000394
Cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-06-22 for the medicinal ingredient thiotepa. Screening…Organization: Health Canada
September 2022
Req # A-2022-000421
All receipts for the expense referred to in Sessional Paper 8555-441-494, tabled in the House of Commons on June 8, 2022, with the following vendor, amount, date of expenditure, and file number: Gilles Blais Distribution, $77.32, March 17th, 2022,…Organization: Health Canada
September 2022
Req # A-2022-000428
All receipts for the expense referred to in Sessional Paper 8555-441-494, tabled in the House of Commons on June 8, 2022, with the following vendor, amount, date of expenditure, and file number: Food Fare QPS WI, $142.40 March 25th, 2022, 241926Organization: Health Canada
September 2022
Req # A-2022-000464
Cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-06-22 for the medicinal ingredients lidocaine-prilocaine.Organization: Health Canada
September 2022
Req # A-2022-000630
The driving factors for management in the Health Product and Food Branch (HPFB) and the governing hierarchy, the criteria for achieving the performance pay for all HPFB executives, by position. Records for the following fiscal years. (2019-2020,…Organization: Health Canada
September 2022
Req # A-2022-000660
Le détail en regard de toutes procédures, demandes ou recours actuellement actifs ou en cours ou pendant ou de tout solde qui vous est dû par cette Société. Société : Dizal inc. (NEQ : 1171554497) 108-4000, rue Jean-Marchand, Québec (Québec) G2C 1Y6.Organization: Health Canada
September 2022